Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer
Tuesday, October 11, 2016 - 04:31
in Health & Medicine
A phase III trial of sunitinib has met its primary endpoint of disease-free survival for adjuvant treatment of high-risk renal cell carcinoma after nephrectomy, researchers report.